CytomX Therapeutics (NASDAQ:CTMX) was downgraded by equities researchers at BidaskClub from a “sell” rating to a “strong sell” rating in a report issued on Tuesday.

CTMX has been the subject of a number of other reports. Zacks Investment Research cut shares of CytomX Therapeutics from a “buy” rating to a “hold” rating in a research note on Monday, August 13th. ValuEngine raised shares of CytomX Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday, June 2nd. SunTrust Banks assumed coverage on shares of CytomX Therapeutics in a research note on Friday, June 1st. They set a “buy” rating and a $38.00 price target for the company. Finally, Cantor Fitzgerald set a $40.00 price target on shares of CytomX Therapeutics and gave the stock a “buy” rating in a research note on Wednesday, May 16th. One analyst has rated the stock with a sell rating, two have issued a hold rating and nine have issued a buy rating to the company’s stock. CytomX Therapeutics currently has a consensus rating of “Buy” and an average target price of $38.38.

CTMX stock opened at $18.98 on Tuesday. CytomX Therapeutics has a 12 month low of $16.26 and a 12 month high of $35.00. The stock has a market cap of $905.57 million, a P/E ratio of -17.14 and a beta of 0.83.

CytomX Therapeutics (NASDAQ:CTMX) last released its quarterly earnings results on Wednesday, August 8th. The biotechnology company reported ($0.35) EPS for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.01). CytomX Therapeutics had a negative return on equity of 74.84% and a negative net margin of 44.46%. The firm had revenue of $21.34 million for the quarter, compared to analysts’ expectations of $16.48 million. analysts predict that CytomX Therapeutics will post -1.5 earnings per share for the current year.

In other CytomX Therapeutics news, insider Sean A. Mccarthy sold 13,052 shares of the business’s stock in a transaction dated Monday, July 2nd. The shares were sold at an average price of $23.42, for a total value of $305,677.84. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Debanjan Ray sold 3,000 shares of the business’s stock in a transaction dated Monday, July 2nd. The shares were sold at an average price of $22.56, for a total transaction of $67,680.00. Following the completion of the sale, the chief financial officer now directly owns 8,928 shares of the company’s stock, valued at $201,415.68. The disclosure for this sale can be found here. Over the last three months, insiders sold 41,629 shares of company stock valued at $967,572. 8.50% of the stock is owned by corporate insiders.

Institutional investors have recently added to or reduced their stakes in the business. Great West Life Assurance Co. Can boosted its position in CytomX Therapeutics by 174.6% in the 2nd quarter. Great West Life Assurance Co. Can now owns 4,943 shares of the biotechnology company’s stock valued at $113,000 after buying an additional 3,143 shares during the period. SG Americas Securities LLC purchased a new stake in CytomX Therapeutics in the 2nd quarter valued at about $119,000. WINTON GROUP Ltd purchased a new stake in CytomX Therapeutics in the 1st quarter valued at about $205,000. Xact Kapitalforvaltning AB purchased a new stake in CytomX Therapeutics in the 2nd quarter valued at about $206,000. Finally, First Republic Investment Management Inc. purchased a new stake in CytomX Therapeutics in the 1st quarter valued at about $216,000. 72.17% of the stock is owned by institutional investors.

About CytomX Therapeutics

CytomX Therapeutics, Inc operates as an oncology-focused biopharmaceutical company in the United States. The company develops a novel class of investigational antibody therapeutics based on its Probody technology platform for the treatment of cancer. Its product candidates in clinical stage include CX-072, a Probody therapeutic targeting programmed cell death ligand 1 anti-cancer target; CX-2009, a Probody drug conjugate (PDC) against CD166 novel tumor antigen; BMS-986249, a CTLA-4 Probody therapeutic drug; CX-2029, a PDC targeting CD71; and CX-188, a Probody therapeutic targeting PD-1 anti-cancer target.

Read More: Fundamental Analysis – How It Helps Investors

Analyst Recommendations for CytomX Therapeutics (NASDAQ:CTMX)

Receive News & Ratings for CytomX Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.